Lotivibart vs UVAX-1107
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV envelope · full HIV pipeline
Lotivibart
Developed by ViiV Healthcare
NCT04871113 · Phase 2 · completed
Participants were randomized among dose cohorts, but the study was open-label, had no placebo or active comparator during monotherapy, and included only 6 to 16 participants per cohort. The primary endpoint was the surrogate measure of maximum decline in HIV-1 RNA and was reported descriptively without a formal comparative efficacy test, so the findings do not establish comparative treatment benefit.
Next expected readout: January 2027 · NCT07053384 (registry estimate)
Reported efficacy
Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase); Number of Participants With Adverse Events (AEs) - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase); Number of Participants With Worst-case Maximum Grade 2-4 Increase in Post-baseline Values of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Compared to the Baseline Values - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase); Number of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Findings - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase); Number of Participants With Grade 2-4 Injection Site Reactions (ISR) - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase): Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase): Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) — Baseline (Day 1): 12258.5 Copies per milliliter (copies/mL) (range 1351 to 173710); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12014.5 Copies per milliliter (copies/mL) (range -171577 to -1312) | Part 1: GSK3810109A 280 mg IV — Baseline (Day 1): 30833 Copies per milliliter (copies/mL) (range 5938 to 104585); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -26826.5 Copies per milliliter (copies/mL) (range -103583 to -5899) | Part 2: GSK3810109A 700 mg IV — Baseline (Day 1): 25466 Copies per milliliter (copies/mL) (range 7180 to 110387); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -25966 Copies per milliliter (copies/mL) (range -107218 to -6944) | Part 2: GSK3810109A 70 mg IV — Baseline (Day 1): 25689.5 Copies per milliliter (copies/mL) (range 7225 to 683576); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -14720.5 Copies per milliliter (copies/mL) (range -197793 to -4382) | Part 2: GSK3810109A 700 mg Subcutaneously (SC) — Baseline (Day 1): 23146 Copies per milliliter (copies/mL) (range 131 to 181078); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12584 Copies per milliliter (copies/mL) (range -178423 to -69) (not_applicable)
Result source: NCT04871113
UVAX-1107
Developed by Uvax Bio
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lotivibart | UVAX-1107 |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not reported | —Not reported |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not reported | —Not reported |
| CD4 count, change (week 48) | —Not reported | —Not reported |
HIV-1 RNA below 50 copies/mL (week 48)
- Lotivibart
- —Not reported
- UVAX-1107
- —Not reported
HIV-1 RNA 50 copies/mL or more (week 48)
- Lotivibart
- —Not reported
- UVAX-1107
- —Not reported
CD4 count, change (week 48)
- Lotivibart
- —Not reported
- UVAX-1107
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
UVAX-1107: no structured comparison results are available for HIV.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lotivibart: 3 of 4 rows · UVAX-1107: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lotivibart |
|---|---|
| Dropout rate | —700 mg IVa NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 show 12 more results—700 mg SC NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —700 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —700 mg SC NCT04871113 · Phase 2 · combination · HIV · phase 2 0%280 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —280 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —70 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —70 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 0%40 mg/kg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —40 mg/kg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 12.5%3000 mg + rHuPH20 NCT05291520 · Phase 1 · combination 0%60 mg/kg NCT05291520 · Phase 1 · monotherapy 0%20 mg/kg + rHuPH20 NCT05291520 · Phase 1 · combination |
| Discontinued due to AEs | —700 mg IVa NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 show 12 more results—700 mg SC NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —700 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —700 mg SC NCT04871113 · Phase 2 · combination · HIV · phase 2 —280 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —280 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —70 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —70 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —40 mg/kg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —40 mg/kg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —3000 mg + rHuPH20 NCT05291520 · Phase 1 · combination —60 mg/kg NCT05291520 · Phase 1 · monotherapy —20 mg/kg + rHuPH20 NCT05291520 · Phase 1 · combination |
| Serious AEs | 0%700 mg IVa NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 show 12 more results0%700 mg SC NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 18.8%700 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 25%700 mg SC NCT04871113 · Phase 2 · combination · HIV · phase 2 0%280 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 0%280 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 0%70 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 12.5%70 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 0%40 mg/kg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 12.5%40 mg/kg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 0%3000 mg + rHuPH20 NCT05291520 · Phase 1 · combination 0%60 mg/kg NCT05291520 · Phase 1 · monotherapy 0%20 mg/kg + rHuPH20 NCT05291520 · Phase 1 · combination |
| Most frequent reported AEs | 700 mg IVa influenza 12.5% rhinitis 12.5% aspartate aminotransferase increased 6.3% NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 show 12 more results700 mg SC headache 18.8% blood creatine phosphokinase increased 12.5% neutropenia 12.5% NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 700 mg IV upper respiratory tract infection 18.8% anaemia 12.5% anogenital warts 6.3% NCT04871113 · Phase 2 · combination · HIV · phase 2 700 mg SC neutropenia 12.5% pharyngitis 12.5% tonsillitis 12.5% NCT04871113 · Phase 2 · combination · HIV · phase 2 280 mg IV abdominal pain 16.7% asthenia 16.7% bronchitis 16.7% NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 280 mg IV depression 16.7% hypertension 16.7% influenza like illness 16.7% NCT04871113 · Phase 2 · combination · HIV · phase 2 70 mg IV covid-19 12.5% alanine aminotransferase increased 6.3% anal abscess 6.3% NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 70 mg IV upper respiratory tract infection 12.5% vomiting 12.5% abdominal pain 6.3% NCT04871113 · Phase 2 · combination · HIV · phase 2 40 mg/kg IV abdominal pain 12.5% blood creatine phosphokinase increased 12.5% covid-19 12.5% NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 40 mg/kg IV covid-19 25% proctitis gonococcal 25% syphilis 25% NCT04871113 · Phase 2 · combination · HIV · phase 2 3000 mg + rHuPH20 injection site erythema 100% injection site bruising 25% injection site pain 25% NCT05291520 · Phase 1 · combination 60 mg/kg medical device site dermatitis 12.5% muscle tightness 12.5% covid-19 0% NCT05291520 · Phase 1 · monotherapy 20 mg/kg + rHuPH20 injection site erythema 87.5% upper respiratory tract infection 25% headache 12.5% NCT05291520 · Phase 1 · combination |
Notes
- aPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lotivibart
show 4 more results
show 4 more results
show 4 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lotivibart's landscape · UVAX-1107's landscape